CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4.1% – What’s Next?

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price traded down 4.1% during mid-day trading on Thursday . The company traded as low as $49.22 and last traded at $50.86. 1,325,701 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 2,376,089 shares. The stock had previously closed at $53.02.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Barclays boosted their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday. The Goldman Sachs Group cut their price target on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Stock Down 5.0 %

The firm has a 50 day simple moving average of $42.25 and a 200-day simple moving average of $46.06. The stock has a market cap of $4.11 billion, a P/E ratio of -10.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of large investors have recently modified their holdings of the business. Boston Family Office LLC boosted its holdings in shares of CRISPR Therapeutics by 2.2% in the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after purchasing an additional 213 shares in the last quarter. Bedell Frazier Investment Counselling LLC raised its position in CRISPR Therapeutics by 0.8% during the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after purchasing an additional 218 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in CRISPR Therapeutics by 1.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after acquiring an additional 231 shares during the period. Intellectus Partners LLC grew its holdings in CRISPR Therapeutics by 3.6% during the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock worth $281,000 after acquiring an additional 250 shares during the period. Finally, Farrow Financial Inc. grew its holdings in CRISPR Therapeutics by 1.4% during the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after acquiring an additional 270 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.